Accretion Pharmaceuticals IPO Listing: Stock lists at 22% discount on NSE SME

Accretion Pharma IPO Listing: Stock Hits Upper Circuit on Debut, but Investors Suffer Double-Digit Losses

Accretion Pharma made its debut on the NSE SME platform today following a successful Initial Public Offering (IPO) earlier this month.

Despite hitting the upper circuit limit shortly after listing, the stock opened at a sharp discount to its issue price, leaving IPO investors in the red from day one.

The ₹29.75 crore IPO, which ran from May 12 to May 16, garnered strong interest from investors across segments. However, the listing failed to meet expectations.

Shares were issued at ₹101 per piece but debuted at just ₹79—a steep 21.78% discount. The stock later locked in the 5% upper circuit and closed the day at ₹82.95, still down 17.87% from the IPO price.

This underwhelming debut has sparked concern among retail investors, especially as the SME IPO space has seen a surge of activity and speculation in recent months.

Strong Demand, Weak Listing

Accretion Pharma’s IPO was oversubscribed by 7.67 times, indicating strong demand in the primary market. The detailed subscription breakdown is as follows:

• Qualified Institutional Buyers (QIBs): 12.14 times
• Non-Institutional Investors (NIIs): 4.28 times
• Retail Individual Investors (RIIs): 10.54 times

Despite this robust participation, especially from institutional and retail investors, the listing failed to deliver listing gains. The poor debut suggests that valuation concerns, market volatility, or weak secondary market sentiment may have outweighed the enthusiasm seen during the subscription period.

IPO Proceeds: Deployment Strategy

Accretion Pharma has outlined a clear strategy for the utilization of funds raised through the IPO, aimed at scaling operations and strengthening its balance sheet. Here’s a breakdown of how the ₹29.75 crore will be deployed:

• ₹2.70 crore – Purchase of new equipment and advanced machinery to enhance manufacturing capabilities
• ₹4.66 crore – Upgradation and modernization of the existing manufacturing facility
• ₹99.2 lakh – Partial repayment or prepayment of secured borrowings
• ₹14.68 crore – Working capital requirements to support day-to-day operations and expansion
• Remaining balance – General corporate purposes including administrative expenses and contingencies

The investment in manufacturing infrastructure and debt reduction is expected to boost operational efficiency and support the company’s expansion plans, especially in international markets.

Company Overview: A Rising Pharma Player

Established in 2012, Accretion Pharma is a Gujarat-based pharmaceutical manufacturer focused on producing tablets, capsules, and a range of healthcare formulations. In addition to its own branded products, the company also provides contract manufacturing services to other pharma companies—a model that offers scalability with controlled risk.

Accretion Pharma’s manufacturing facility complies with several quality standards, enabling the company to cater to both domestic and international markets. The company currently exports its products to over 20 countries, making it a growing name in the small-to-mid-sized pharma manufacturing space.

Financial Performance: Solid Growth Momentum

Over the past three years, Accretion Pharma has shown strong improvement in both revenue and profitability, reflecting its growing market presence and operational maturity.

Key Financial Highlights:

• FY 2021–22: Net profit of ₹8 lakh
• FY 2022–23: Net profit rose modestly to ₹10 lakh
• FY 2023–24: Net profit surged to ₹3.88 crore
• April–December 2024 (FY 2024–25 YTD): Net profit stands at ₹5.24 crore with revenue of ₹35.75 crore

The company’s revenue has expanded at a Compound Annual Growth Rate (CAGR) of over 22%, reaching ₹33.94 crore in FY 2023–24. This strong upward trajectory suggests that the business is scaling rapidly and becoming more profitable with time.

The turnaround in profitability from lakhs to crores within two years indicates enhanced operational efficiency, likely driven by increased production capacity and better utilization of fixed assets.

Market Sentiment: A Reality Check for SME IPOs

While Accretion Pharma’s fundamentals seem promising, its listing performance is a stark reminder of the risks associated with SME IPOs. These issues tend to be less liquid and more volatile than their mainboard counterparts.

A significant listing-day loss, despite healthy subscription numbers, hints at either aggressive pricing or broader market skepticism.

Several market analysts believe that the IPO may have been overvalued, or that investor enthusiasm was driven more by momentum than fundamentals.

This scenario often plays out in the SME space, where retail investors chase high returns, sometimes overlooking the risks tied to lower market capitalization and limited trading volume.

Investor Takeaway: What Should You Do Now?

For investors who entered during the IPO, the immediate loss of 17.87% is undoubtedly disappointing. However, whether to hold or exit should depend on individual risk appetite and long-term view.

Here are a few considerations:

• Hold if you believe in the company’s long-term growth story, especially with its international reach and improving profit margins.
• Exit if you were seeking only listing gains and are uncomfortable with the possibility of prolonged volatility in the SME segment.
• Wait and Watch if you’re uncertain; upcoming quarterly results and delivery on IPO promises (such as capex deployment and debt reduction) could provide more clarity.

Final Thoughts

Accretion Pharma’s IPO journey has been a mixed bag—strong fundamentals and investor interest, but a poor listing that caught many off guard. While the company’s operational and financial trajectory looks solid, the listing discount is a cautionary tale about the speculative nature of SME IPOs.

Investors are advised to analyze not just the growth numbers, but also the valuations and market conditions when considering such investments.

In the case of Accretion Pharma, the true verdict will emerge not on Day 1 of listing, but over the next few quarters as the company executes its expansion strategy and delivers results.